Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Neuroendocrine cancer

Surufatinib — a novel oral agent for neuroendocrine tumours

In two phase III trials, surufatinib, a novel oral tyrosine kinase inhibitor targeting immune cells and angiogenesis, was effective for treating pancreatic and extra-pancreatic neuroendocrine tumours. These findings further expand the therapeutic options for patients with gastro–entero–pancreatic, thymic and lung neuroendocrine tumours.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Hofland, J., Kaltsas, G. & de Herder, W. W. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr. Rev. 41, 371–403 (2020).

    Article  Google Scholar 

  2. 2.

    Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).

    CAS  Article  Google Scholar 

  3. 3.

    Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387, 968–977 (2016).

    CAS  Article  Google Scholar 

  4. 4.

    Cai, L. et al. Role of tumor-associated macrophages in the clinical course of pancreatic neuroendocrine tumors (PanNETs). Clin. Cancer Res. 25, 2644–2655 (2019).

    CAS  Article  Google Scholar 

  5. 5.

    Lyons, Y. A. et al. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget 8, 96496–96505 (2017).

    Article  Google Scholar 

  6. 6.

    Xu, J. et al. Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib/II trial. Clin. Cancer Res. 25, 3486–3494 (2019).

    CAS  PubMed  Google Scholar 

  7. 7.

    Xu, J. M. et al. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget 8, 42076–42086 (2017).

    Article  Google Scholar 

  8. 8.

    Xu, J. et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30493-9 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Xu, J. et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30496-4 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Dasari, A. et al. Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs). J. Clin. Oncol. 38, 4610–4610 (2020).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Gregory Kaltsas.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Koumarianou, A., Kaltsas, G. Surufatinib — a novel oral agent for neuroendocrine tumours. Nat Rev Endocrinol 17, 9–10 (2021). https://doi.org/10.1038/s41574-020-00439-0

Download citation

Further reading

Search

Quick links